

ABBVIE LTD ABPI DISCLOSURE REQUIREMENTS ON TRANSFERS OF VALUE TO MEMBERS OF THE PUBLIC INCLUDING PATIENTS AND JOURNALISTS FOR FINANCIAL YEAR 2023

Annual Disclosure of Contracted Services Provided by The Public						
	Number of Members of the Public Contracted	Country	Contracted Services Provided	Description of Support	Total	
Members of the Public*	8	UK	Contracted Services	Fees	Presentation at AbbVie session at external conference	£6,000.00
				Expenses		£160.00
				Fees	Consultancy services	£15,900
				Fees	Advisory board / group consultancy	£1,003.75
Patients	60	UK	Contracted Services	Fees	Services include participation in advisory boards, speaking at meetings and assistance with creating patient educational materials	£13,294.93
				Expenses		£759.35
Journalists	9	UK	Contracted Services	Fees	Presentation at AbbVie internal conference	£7,000.00
				Expenses	Advisory board / group consultancy	£2,660.00

*Other Members of the Public including Caregivers, Patient Advocates, and Models

ABBVIE LTD TRANSPARENCY DISCLOSURE METHODOLOGICAL NOTES FOR REPORTING YEAR 2023

As a member company of European Federation of Pharmaceutical Industries and Associations (EFPIA) and Association of the British Pharmaceutical Industry (ABPI), **AbbVie Ltd** is committed to ensuring that the nature and scope of transfers of value (ToV) with UK members of the public, including patients and journalists, are clear and transparent. Therefore, AbbVie has published applicable ToV provided directly or indirectly to UK members of the public for the 2023 calendar year.

This Methodological Note provides guidance on how AbbVie has recorded and publicly reported this information in aggregate in accordance with the current edition of the ABPI Code of Practice.

Reporting period / Reportable ToV:

The AbbVie Ltd 2023 disclosure includes applicable ToV during the period between 1st January and 31st December 2023. The applicable ToV relate to payments made within the disclosure period. Payments made from 1st January 2024 will be considered for the next report.

Transparency Acknowledgment from UK members of the public, including patients and journalists:

Agreements between AbbVie and UK members of the public, including patients and journalists, relating to ToV have included a Transparency section which included notification of AbbVie's Transparency disclosure obligations.

Cross Border Interactions:

These ToV include engagements between AbbVie Global and UK members of the public, including patients and journalists, where these have occurred. For example, where UK members of the public, patients or journalists participated in an AbbVie global supported programme.

Members of the Public, including Patients and Journalists Definitions:

Other Members of the Public including Caregivers, Patient Advocates, and Models

Description: Services completed by other members of the public including caregivers of patients, patient advocates, models and other reportable recipients to provide AbbVie with expert insights, perspectives, and feedback, including providing insights into their lived experiences and participating in photo shoots and video recordings.

Patients

Description: Services completed by patients to provide AbbVie with expert insights, perspectives, and feedback on the patient experience, including activities such as speaking at AbbVie-organised meetings, advising or providing feedback on projects or activities (e.g., patient materials or patient-facing campaigns), providing insights into their lived experiences, participating in advisory board meetings and in video or audio recordings.

Journalists

Description: Services completed by journalists to provide AbbVie with expert insights into how health conditions are reported in the media, including advisory board participation and consultation.

ToV Definitions:

- Contracted Services: Fees such as:
 - Speaking at AbbVie internal and external meetings
 - Assistance with training
 - Writing articles and/or publications
 - Participating in advisory boards
 - Advising on the design of clinical trials

- Contracted services: Expenses, such as:
 - Flights
 - Hotel
 - Other transportations costs (mileage, train, taxi, bus, underground, parking)

Date Methodology:

AbbVie followed the date methodology when determining which ToV are in scope for current reporting cycle:

- **Event Date** is defined as the date the expense occurred. ToV related to the following categories will use the Event Date when determining applicability for current year reporting requirements (e.g., did the event occur within the reporting period 1st January to 31st December 2023).
 - Fee for Service and Consultancy: Expenses
- **Paid Date** is defined as the date the payment was paid to the recipient. ToV related to the following categories use the Paid Date when determining applicability for current year reporting requirements (e.g., did the payment occur within the reporting period 1st January to 31st December 2023).
 - Contracted services: Fees

Value Added Tax (VAT):

Where applicable, disclosure of payments does not include VAT.

Withholding Taxes:

Where applicable, for services provided in locations outside of United Kingdom, ToV amounts will be reported as outlined in the contract agreement.

Currency:

All information is reported in Pound Sterling (GBP).

Exchange Rate:

Where ToV were captured in foreign currency, amounts were converted to local currency based on AbbVie Treasury Monthly Average Rates.

Multiyear Contracts:

Activities with ToV crossing calendar years may have the contracted full amount disclosed using the date of last payment.